U.S. FDA Accepts for Priority Review the Biologics License Application for Investigational 15-valent Pneumococcal Vaccine

In COVID-19, Latest News by Precision Vaccinations

The U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
Merck announced the FDA set a Prescription Drug User Fee Act, or target action date, of July 18, 2021. 

Read More